{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:15:19Z","timestamp":1790414119110,"version":"4.1.0"},"reference-count":51,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Emerging Microbes & Infections"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/emi.2016.123","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T08:21:30Z","timestamp":1478679690000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":66,"title":["Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria"],"prefix":"10.1080","volume":"5","author":[{"given":"Wei","family":"Sun","sequence":"first","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A","family":"Weingarten","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Xu","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Southall","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Dai","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Shinn","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip E","family":"Sanderson","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R","family":"Williamson","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M","family":"Frank","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"e_1_3_2_1_1","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States 2013. Atlanta GA: CDC 2016; Available at http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/(accessed on 15 June 2016)."},{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1038\/nm1145","article-title":"Antibacterial resistance worldwide: causes, challenges and responses","volume":"10","author":"Levy SB","year":"2004","unstructured":"LevySB,MarshallB.Antibacterial resistance worldwide: causes, challenges and responses.Nat Med2004 Dec; 10(12 Suppl):S122\u2013S129.","journal-title":"Nat Med"},{"key":"e_1_3_2_3_1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/647952","article-title":"Antimicrobial susceptibility testing: a review of general principles and contemporary practices","volume":"1","author":"Jorgensen JH","year":"2009","unstructured":"JorgensenJH,FerraroMJ.Antimicrobial susceptibility testing: a review of general principles and contemporary practices.Clin Infect Dis2009; 149:1749\u20131755.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tibtech.2012.12.006","article-title":"Combination approaches to combat multidrug-resistant bacteria","volume":"31","author":"Worthington RJ","year":"2013","unstructured":"WorthingtonRJ,MelanderC.Combination approaches to combat multidrug-resistant bacteria.Trends Biotechnol2013 Mar; 31:177\u2013184.","journal-title":"Trends Biotechnol"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s10096-014-2124-9","article-title":"Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review","volume":"33","author":"Poulikakos P","year":"2014","unstructured":"PoulikakosP,TansarliGS,FalagasME.Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.Eur J Clin Microbiol Infect Dis2014; 33:1675\u20131685.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"e_1_3_2_6_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13054-014-0596-8","article-title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study","volume":"18","author":"Zilberberg MD","year":"2014","unstructured":"ZilberbergMD,ShorrAF,MicekST,Vazquez-GuillametC,KollefMH.Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study.Crit Care2014; 18:6.","journal-title":"Crit Care"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1128\/JCM.00932-16","article-title":"Verification of an automated, digital dispensing platform for at-will broth microdilution antimicrobial susceptibility testing","volume":"54","author":"Smith KP","year":"2016","unstructured":"SmithKP,KirbyJE.Verification of an automated, digital dispensing platform for at-will broth microdilution antimicrobial susceptibility testing.J Clin Microbiol2016; 54:2288\u20132293.","journal-title":"J Clin Microbiol"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijid.2014.12.022","article-title":"The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit","volume":"31","author":"Cornejo-Juarez P","year":"2015","unstructured":"Cornejo-JuarezP,Vilar-CompteD,Perez-JimenezC,Namendys-SilvaSA,Sandoval-HernandezS,Volkow-FernandezP.The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit.Int J Infect Dis2015; 31:31\u201334.","journal-title":"Int J Infect Dis"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/cc4995","article-title":"Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis","volume":"10","author":"Garnacho-Montero J","year":"2006","unstructured":"Garnacho-MonteroJ,Aldabo-PallasT,Garnacho-MonteroCet al.Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis.Crit Care2006; 10:R111.","journal-title":"Crit Care"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd4675","article-title":"Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?","volume":"14","author":"Brown D","year":"2015","unstructured":"BrownD.Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?Nat Rev Drug Discov2015; 14:821\u2013832.","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1465-0691.2004.1007.x","article-title":"Antimicrobial drug development - the past, the present, and the future","volume":"10","author":"Powers JH","year":"2004","unstructured":"PowersJH.Antimicrobial drug development - the past, the present, and the future.Clin Microbiol Infec2004; 10:23\u201331.","journal-title":"Clin Microbiol Infec"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/fmb.12.75","article-title":"Repurposing screens identify rifamycins as potential broad-spectrum therapy for multidrug-resistant Acinetobacter baumannii and select agent microorganisms","volume":"7","author":"Chromy BA","year":"2012","unstructured":"ChromyBA,ElsheikhM,ChristensenTL,et al.Repurposing screens identify rifamycins as potential broad-spectrum therapy for multidrug-resistant Acinetobacter baumannii and select agent microorganisms.Future Microbiol2012; 7:1011\u20131020.","journal-title":"Future Microbiol"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1038\/emi.2014.53","article-title":"Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library","volume":"3","author":"Feng J","year":"2014","unstructured":"FengJ,WangT,ShiWL,et al.Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library.Emerg Microbes Infect2014; 3:e49.","journal-title":"Emerg Microbes Infect"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1073\/pnas.1504022112","article-title":"Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis","volume":"7","author":"Harbut MB","year":"2015","unstructured":"HarbutMB,VilchezeC,LuoX,et al.Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis.Proc Natl Acad Sci USA2015; 7112:4453\u20134458.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7326\/M16-0291","article-title":"Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration-approved antibiotics, 2010-2015","volume":"165","author":"Deak D","year":"2016","unstructured":"DeakD,OuttersonK,PowersJH,KesselheimAS.Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration-approved antibiotics, 2010-2015.Ann Intern Med2016; 165:363\u2013372.","journal-title":"Ann Intern Med"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001862","article-title":"The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics","volume":"3","author":"Huang RL","year":"2011","unstructured":"HuangRL,SouthallN,WangYH,et al.The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.Sci Transl Med2011; 380ps16.","journal-title":"Sci Transl Med"},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1039\/b922051h","article-title":"Lateral patch-clamping in a standard 1536-well microplate format","volume":"10","author":"Tang KC","year":"2010","unstructured":"TangKC,ReboudJ,KwokYL,PengSL,YobasL.Lateral patch-clamping in a standard 1536-well microplate format.Lab Chip2010; 10:1044\u20131050.","journal-title":"Lab Chip"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1021\/ac900622b","article-title":"Microfractionation revisited: a 1536 well high resolution screening assay","volume":"1","author":"Giera M","year":"2009","unstructured":"GieraM,HeusF,JanssenL,KoolJ,LingemanH,IrthH.Microfractionation revisited: a 1536 well high resolution screening assay.Anal Chem2009; 181:5460\u20135466.","journal-title":"Anal Chem"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/toxsci\/kfv141","article-title":"Cell-based high-throughput screening for aromatase inhibitors in the Tox21 10\u2009K library","volume":"147","author":"Chen S","year":"2015","unstructured":"ChenS,HsiehJH,HuangRet al.Cell-based high-throughput screening for aromatase inhibitors in the Tox21 10\u2009K library.Toxicol Sci2015; 147:446\u2013457.","journal-title":"Toxicol Sci"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","first-page":"11473","DOI":"10.1073\/pnas.0604348103","article-title":"Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries","volume":"1","author":"Inglese J","year":"2006","unstructured":"IngleseJ,AuldDS,JadhavA,et al.Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.Proc Natl Acad Sci USA2006; 1103:11473\u201311478.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1128\/AAC.00014-16","article-title":"Horizontal transfer of carbapenemase-encoding plasmids and comparison with hospital epidemiology data","volume":"60","author":"Hardiman CA","year":"2016","unstructured":"HardimanCA,WeingartenRA,ConlanSet al.Horizontal transfer of carbapenemase-encoding plasmids and comparison with hospital epidemiology data.Antimicrob Agents Chemother2016; 60:4910\u20134919.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_2_22_1","doi-asserted-by":"crossref","first-page":"80ps16","DOI":"10.1126\/scitranslmed.3001862","article-title":"The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics","volume":"3","author":"Huang R","year":"2011","unstructured":"HuangR,SouthallN,WangY,et al.The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.Sci Transl Med2011; 3:80ps16.","journal-title":"Sci Transl Med"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1038\/srep03743","article-title":"Chemical signatures and new drug targets for gametocytocidal drug development","volume":"4","author":"Sun W","year":"2014","unstructured":"SunW,TanakaTQ,MagleCT,et al.Chemical signatures and new drug targets for gametocytocidal drug development.Sci Rep2014; 4:3743.","journal-title":"Sci Rep"},{"key":"e_1_3_2_24_1","unstructured":"Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-10th ed. Document M07-A10. vol. 35. Wayne PA: CLSI 2015."},{"key":"e_1_3_2_25_1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/1087057114521867","article-title":"A new bliss independence model to analyze drug combination data","volume":"19","author":"Zhao W","year":"2014","unstructured":"ZhaoW,SachsenmeierK,ZhangLJ,SultE,HollingsworthRE,YangH.A new bliss independence model to analyze drug combination data.J Biomol Screen2014; 19:817\u2013821.","journal-title":"J Biomol Screen"},{"key":"e_1_3_2_26_1","article-title":"Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput drug repurposing screens","volume":"8","author":"Sun W","year":"2013","unstructured":"SunW,ParkYD,SuguiJA,et al.Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput drug repurposing screens.Plos ONE2013; 8: e70506.","journal-title":"Plos ONE"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ab.2009.07.003","article-title":"A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel","volume":"1","author":"Titus SA","year":"2009","unstructured":"TitusSA,BeachamD,ShahaneSAet al.A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.Anal Biochem2009; 1394:30\u201338.","journal-title":"Anal Biochem"},{"key":"e_1_3_2_28_1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/08860229909085109","article-title":"Oxidant mechanisms in gentamicin nephrotoxicity","volume":"21","author":"Walker PD","year":"1999","unstructured":"WalkerPD,BarriY,ShahSV.Oxidant mechanisms in gentamicin nephrotoxicity.Ren Fail1999; 21:433\u2013442.","journal-title":"Ren Fail"},{"key":"e_1_3_2_29_1","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters, version 4.0","year":"2014","unstructured":"EUCAST.Breakpoint tables for interpretation of MICs and zone diameters, version 4.0.V\u00e4xj\u00f6, Sweden: EUCAST Laboratory for Antimicrobial Susceptibility Testing.2014."},{"key":"e_1_3_2_30_1","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1093\/jac\/dkv163","article-title":"Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections","volume":"70","author":"Aguinagalde L","year":"2015","unstructured":"AguinagaldeL,Diez-MartinezR,YusteJet al.Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections.J Antimicrob Chemother2015; 70:2608\u20132617.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/jac\/dkt150","article-title":"Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?","volume":"68","author":"Schon T","year":"2013","unstructured":"SchonT,JureenP,ChryssanthouE,et al.Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?J Antimicrob Chemother2013; 68:2074\u20132077.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_2_32_1","first-page":"282ra249","article-title":"Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection","volume":"7","author":"He S","year":"2015","unstructured":"HeS,LinB,ChuV,et al.Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.Sci Transl Med2015; 7:282ra249.","journal-title":"Sci Transl Med"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","article-title":"3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro","volume":"82","author":"Mitsuya H","year":"1985","unstructured":"MitsuyaH,WeinholdKJ,FurmanPA,et al.3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro.Proc Natl Acad Sci USA1985; 82:7096\u20137100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.cell.2014.07.011","article-title":"Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate","volume":"158","author":"Lisewski AM","year":"2014","unstructured":"LisewskiAM,QuirosJP,NgCLet al.Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate.Cell2014; 158:916\u2013928.","journal-title":"Cell"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/emm.2003.9","article-title":"Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit","volume":"35","author":"Jeon KI","year":"2003","unstructured":"JeonKI,ByunMS,JueDM.Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit.Exp Mol Med2003; 35:61\u201366.","journal-title":"Exp Mol Med"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1104\/pp.40.5.785","article-title":"Light-dependent volume changes and reactions in chloroplasts. I. Action of alkenylsuccinic acids and phenylmercuric acetate and possible relation to mechanisms of stomatal control","volume":"40","author":"Siegenthaler PA","year":"1965","unstructured":"SiegenthalerPA,PackerL.Light-dependent volume changes and reactions in chloroplasts. I. Action of alkenylsuccinic acids and phenylmercuric acetate and possible relation to mechanisms of stomatal control.Plant Physiol1965; 40:785\u2013791.","journal-title":"Plant Physiol"},{"key":"e_1_3_2_37_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2133.2011.10571.x","article-title":"The antifungal mechanism of action of zinc pyrithione","volume":"165","author":"Reeder NL","year":"2011","unstructured":"ReederNL,XuJ,YoungquistRS,SchwartzJR,RustRC,SaundersCW.The antifungal mechanism of action of zinc pyrithione.Br J Dermatol2011; 165(Suppl 2):9\u201312.","journal-title":"Br J Dermatol"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1093\/nar\/4.10.3573","article-title":"DNA double-strand breaks and alkali-labile bonds produced by bleomycin","volume":"4","author":"Povirk LF","year":"1977","unstructured":"PovirkLF,WubterW,KohnleinW,HutchinsonF.DNA double-strand breaks and alkali-labile bonds produced by bleomycin.Nucleic Acids Res1977; 4:3573\u20133580.","journal-title":"Nucleic Acids Res"},{"key":"e_1_3_2_39_1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1128\/AAC.6.6.712","article-title":"Antimicrobial actions of hexachlorophene: inhibition of respiration in Bacillus megaterium","volume":"6","author":"Frederick JJ","year":"1974","unstructured":"FrederickJJ,CornerTR,GerhardtP.Antimicrobial actions of hexachlorophene: inhibition of respiration in Bacillus megaterium.Antimicrob Agents Chemother1974; 6:712\u2013721.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_2_40_1","first-page":"950","article-title":"Tetracyclines: new look at old antibiotic. I. Clinical pharmacology, mechanism of action, and untoward effects","volume":"78","author":"Siegel D","year":"1978","unstructured":"SiegelD.Tetracyclines: new look at old antibiotic. I. Clinical pharmacology, mechanism of action, and untoward effects.NY State J Med1978; 78:950\u2013956.","journal-title":"NY State J Med"},{"key":"e_1_3_2_41_1","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1128\/AAC.06268-11","article-title":"Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens","volume":"56","author":"Qureshi ZA","year":"2012","unstructured":"QureshiZA,PatersonDL,PotoskiBA,et al.Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.Antimicrob Agents Chemother2012; 56:2108\u20132113.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_2_42_1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrmicro2319","article-title":"Antibiotic resistance and its cost: is it possible to reverse resistance?","volume":"8","author":"Andersson DI","year":"2010","unstructured":"AnderssonDI,HughesD.Antibiotic resistance and its cost: is it possible to reverse resistance?Nat Rev Microbiol2010; 8:260\u2013271.","journal-title":"Nat Rev Microbiol"},{"key":"e_1_3_2_43_1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun W","year":"2016","unstructured":"SunW,SandersonP,ZhengW.Drug combination therapy increases successful drug repositioning.Drug Discov Today2016; 21:1189\u20131195.","journal-title":"Drug Discov Today"},{"key":"e_1_3_2_44_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","article-title":"Auranofin: repurposing an old drug for a golden new age","volume":"15","author":"Roder C","year":"2015","unstructured":"RoderC,ThomsonMJ.Auranofin: repurposing an old drug for a golden new age.Drugs R D2015; 15:13\u201320.","journal-title":"Drugs R D"},{"key":"e_1_3_2_45_1","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/jac\/dkw024","article-title":"Rifabutin: where do we stand in 2016?","volume":"71","author":"Crabol Y","year":"2016","unstructured":"CrabolY,CatherinotE,VezirisN,JullienV,LortholaryO.Rifabutin: where do we stand in 2016?J Antimicrob Chemother2016; 71:1759\u20131771.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_2_46_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni E","year":"2013","unstructured":"Durante-MangoniE,SignorielloG,AndiniR,et al.Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.Clinical Infectious Diseases2013; 57:349\u2013358.","journal-title":"Clinical Infectious Diseases"},{"key":"e_1_3_2_47_1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1128\/JCM.01121-14","article-title":"When does 2 plus 2 equal 5? a review of antimicrobial synergy testing","volume":"52","author":"Doern CD","year":"2014","unstructured":"DoernCD.When does 2 plus 2 equal 5? a review of antimicrobial synergy testing.J Clin Microbiol2014; 52:4124\u20134128.","journal-title":"J Clin Microbiol"},{"key":"e_1_3_2_48_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(05)67060-2","article-title":"Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial","volume":"366","author":"Aaron SD","year":"2005","unstructured":"AaronSD,VandemheenKL,FerrisW,et al.Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.Lancet2005; 366:463\u2013471.","journal-title":"Lancet"},{"key":"e_1_3_2_49_1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.prrv.2007.04.005","article-title":"Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms","volume":"8","author":"Aaron SD","year":"2007","unstructured":"AaronSD.Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms.Paediatr Respir Rev2007; 8:256\u2013261.","journal-title":"Paediatr Respir Rev"},{"key":"e_1_3_2_50_1","doi-asserted-by":"crossref","first-page":"e009956","DOI":"10.1136\/bmjopen-2015-009956","article-title":"Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol","volume":"6","author":"Dickstein Y","year":"2016","unstructured":"DicksteinY,LeiboviciL,YahavD,et al.Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.BMJ Open2016; 6:e009956.","journal-title":"BMJ Open"},{"key":"e_1_3_2_51_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrclinonc.2011.2","article-title":"Methodological and practical challenges for personalized cancer therapies","volume":"8","author":"Wistuba","year":"2011","unstructured":"WistubaII,GelovaniJG,JacobyJJ,DavisSE,HerbstRS.Methodological and practical challenges for personalized cancer therapies.Nat Rev Clin Oncol2011; 8:135\u2013141.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Emerging Microbes & Infections"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/emi2016123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/emi2016123","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1038\/emi.2016.123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/emi2016123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T12:48:27Z","timestamp":1695300507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1038\/emi.2016.123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1038\/emi.2016.123"],"URL":"https:\/\/doi.org\/10.1038\/emi.2016.123","relation":{},"ISSN":["2222-1751"],"issn-type":[{"value":"2222-1751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=temi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=temi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}